You are here: Industry Insights > Kidney Cancer

News List

Opdivo/Yervoy continues to impress in kidney cancer pharmatimes
March 10, 2020
Bristol-Myers Squibb has announced that its Opdivo (nivolumab) and Yervoy (ipilimumab) combo has demonstrated superior overall survival, complete response rates and objective response rates at 42 months ...
Post-surgery chemo halves risk of recurring rare kidney cancer pharmatimes
March 09, 2020
A new trial has revealed that chemotherapy after surgery can reduce the risk of cancer of the ureter and renal pelvis returning by half.
Merck heaps early pressure on Bristol-Myers' Opdivo with Keytruda's kidney cancer debut fiercepharma
April 23, 2019
Bristol-Myers Squibb investors knew trouble would come for Opdivo when Merck’s Keytruda entered the kidney cancer arena, but that trouble just arrived two months early.
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early fiercepharma
February 20, 2019
The race is on between two Big Pharmas to snag a new indication in kidney cancer, but thanks to new data from Merck & Co., it may not matter who gets there first.
Drug combination may become new standard treatment for advanced kidney cancer europeanpharmaceuticalreview
February 19, 2019
Immunotherapy drug plus targeted agent provided better progression-free survival and shrank tumors in more patients than standard one-drug treatment…
Keytruda combo set to become “standard of care” in kidney cancer pharmaphorum
February 19, 2019
Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a price advantage over BMS’ rival drug.....
Merck/Pfizer up the pressure on BMS in first-line kidney cancer pharmaphorum
February 14, 2019
The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol-Myers Squibb.
BMS gets new OK for Opdivo/Yervoy in kidney cancer pharmaphorum
January 17, 2019
Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal cell carcinoma (RCC), the most common form of kidney cancer.
Make that four drug approvals for Pfizer’s oncology unit in less than two months. In a welcome streak for the pharma giant—what with Lyrica generics looming—the FDA handed out fiercepharma
December 10, 2018
Roche’s immuno-oncology rivals are hurtling toward a showdown in previously untreated kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.
Former Aveo CFO found guilty of misleading investors about prospects for cancer drug fiercepharma
December 10, 2018
The SEC’s two-year battle with Aveo Pharmaceuticals over the company’s embattled kidney cancer drug tivozanib has come to a close with a jury verdict against its former chief financial officer, David Johnston.

Previous page 1 2 3 4 Next page